The American Journal of Endocannabinoid Medicine Officially Launches Under the Haymarket Media US Banner

The launch follows on the heels of Haymarket’s acquisition of AJEM in March 2023; the acquisition expands the medical community’s access to high-quality, trusted, peer-reviewed content on cannabinoid-based therapy.

NEW YORK--(BUSINESS WIRE)--Haymarket Media, Inc. is pleased to announce the all-new American Journal of Endocannabinoid Medicine (AJEM), a peer-reviewed journal focused on cannabinoid-based medicine.

Today’s launch marks a new chapter in the field of endocannabinoid medicine: By joining the Haymarket Medical Network (HMN), AJEM will expand its reach and influence, providing even more valuable content to healthcare professionals (HCPs) in the evolving field of endocannabinoid medicine. AJEM will continue to offer HCPs the latest in endocannabinoid medicine, including peer-reviewed original research, noteworthy news, feature articles, and editorials, as well as the all-new AJEM Live (podcasts and video shorts) and conference coverage from medical meetings worldwide.

“It’s an exciting day in the medical industry as we explore this incredible biological system and ways to safely engage with it. AJEM/Haymarket will bridge the knowledge gap between medical and cannabis,” says Ken Watkins, founder and Brand Director of AJEM. “Medical cannabis science and peer-reviewed research will now reach the doctors who need it the most,” says Watkins.

A trusted source of information on endocannabinoid research since 2019, AJEM provides the endocannabinoid education that doctors never received in medical school, delivered in the form of peer-reviewed research articles, video, podcasts and other engaging mediums.

“As a Haymarket Medical Network (HMN) brand, AJEM will continue to thrive as a reliable resource for the latest advancements, best practices, and evidence-based knowledge in the field of endocannabinoid medicine,” says Mike Graziani, President of Haymarket’s Medical Communications Group.

For more information or sponsorship opportunities, contact Ken Watkins, Brand Director. For manuscript submissions, contact Meg Block Roloff, MPH, Senior Managing Editor.

About the American Journal of Endocannabinoid Medicine

The American Journal of Endocannabinoid Medicine’s (AJEM) mission is to educate healthcare professionals on medicines that engage with the endocannabinoid system (ECS). By presenting clinical research on the role of the ECS in achieving homeostasis and as a therapeutic target, AJEM seeks to improve the practice of evidence-based cannabinoid medicine. AJEM publishes peer-reviewed original research manuscripts and research interpretation, news, and opinion pieces from thought leaders in the field. AJEM’s renowned Editorial Board members assist in the peer-review process and are a diverse group of experts with experience in various cannabinoid medicine disciplines. To learn more, visit www.ajendomed.com.

About Haymarket Medical Network

Haymarket Medical Network reaches healthcare practitioners through a multichannel environment with more than 20 unique brands offered across multiple formats—web, app, print, and live events. Its interconnectivity allows users to move from brand to brand to discover the relevant content they need to make practice-related decisions. The network includes renowned drug database MPR and an expanding portfolio of websites that deliver valuable content covering specific therapeutic areas such as Cardiology Advisor, Neurology Advisor, Infectious Disease Advisor and Cancer Therapy Advisor. To learn more, visit www.haymarketmedicalnetwork.com.